Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment modalities in both the induction and maintenance setting, to manage newly diagnosed MM ever continues. In recent years, the treatment landscape of patients with relapsed refractory multiple myeloma (RRMM) has also changed dramatically following a long list of positive phase III trials. This overview will give an update of pivotal trials in this setting (IKEMA, OPTIMISMM, CANDOR, BELLINI) as well as discusses some new emerging therapies in the field, including CAR T cell therapy, a B-cell maturation antigen T-cell engager and a novel cereblon E3 ligase modulator (CELMoD) agent.

(BELG J HEMATOL 2020;11(5):203-8)